



HEMATOLOGIC MALIGNANCIES

The Evolving Role of Transplant in Newly Diagnosed *TP53* Wild-Type Classical Mantle Cell Lymphoma

Presented by: Paolo F. Caimi, MD, *Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute*

Overview: Autologous HCT as first-line consolidation therapy has been associated with favorable clinical outcomes for patients with newly diagnosed *TP53*-wild type classical MCL who are eligible for transplant. However, its role is changing with the advent of improved induction therapy regimens. This session reviews the recent advances and the importance of response assessment following induction therapy, and ways to make informed clinical decisions for patients.

Learning Objectives:

- Review evidence from clinical trials evaluating the role of autologous hematopoietic cell transplant for newly diagnosed *TP53*-wild type classical mantle cell lymphoma.
- Develop individualized treatment plans for patients with newly diagnosed *TP53*-wild type classical mantle cell lymphoma based on the response to induction therapy.

Novel Approaches for Treating *TP53*-Mutated Classical Mantle Cell Lymphoma

Presented by: Ann S. LaCasce, MD, MMSc, *Dana-Farber Cancer Institute*

Overview: Classical MCL with *TP53* mutation is associated with inferior clinical outcomes to induction chemoimmunotherapy and autologous HCT, especially in younger patients. BTK inhibitor-based regimens are emerging as effective treatment options for patients with previously untreated classical MCL with *TP53* mutation. CAR T-cell therapy also results in favorable response rates in previously treated classical MCL with *TP53* mutation. This session highlights the recent advances that will aid in informed clinical decisions for the treatment of patients with *TP53* mutated MCL.

Learning Objectives:

- Summarize the data from clinical trials evaluating novel treatment options for *TP53* mutated classical mantle cell lymphoma.
- Develop individualized treatment plans for patients with *TP53* mutated classical mantle cell lymphoma.

Relapsed/Refractory Multiple Myeloma: Evidence-Based Approaches to Therapy Selection and Sequencing

Presented by: Shaji K. Kumar, MD, *Mayo Clinic Comprehensive Cancer Center*

Overview: Sequencing therapies in the management of relapsed or refractory multiple myeloma is a dynamic, individualized process that integrates prior treatment history, resistance patterns, patient and disease characteristics, and the expanding array of approved and investigational agents. Clinical trial participation is recommended whenever possible, and risk-adapted strategies should be employed to optimize outcomes. This session provides information on available treatments and strategies for personalizing care is essential to optimize outcomes for patients with multiple myeloma.

Learning Objectives:

- Describe the mechanisms of resistance and clinical factors that guide sequencing of therapies in relapsed/refractory multiple myeloma.
- Evaluate current and emerging therapeutic strategies for relapsed/refractory multiple myeloma.